TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia
Brief Summary: The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia


Options:
A: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
B: Arm Label: Cohort 1 dociparstat; Type: EXPERIMENTAL; Interventions: Drug: Dociparstat sodium | Arm Label: Cohort 1 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 dociparstat; Type: EXPERIMENTAL; Interventions: Drug: Dociparstat sodium | Arm Label: Cohort 2 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 3 dociparstat; Type: EXPERIMENTAL; Interventions: Drug: Dociparstat sodium | Arm Label: Cohort 3 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dociparstat sodium; Assigned to Arm(s): Cohort 1 dociparstat, Cohort 2 dociparstat, Cohort 3 dociparstat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 placebo, Cohort 2 placebo, Cohort 3 placebo
C: Arm Label: Medical; Type: N/A; Interventions: Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux | Arm Label: Intensive; Type: N/A; Interventions: Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux | Intervention Type: DRUG; Name: thromboprophylaxis with low-molecular-weight heparin or fondaparinux; Assigned to Arm(s): Intensive, Medical
D: Arm Label: A: Rivaroxaban short arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto] | Arm Label: B: Rivaroxaban long arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto] | Intervention Type: DRUG; Name: Rivaroxaban 10 MG Oral Tablet [Xarelto]; Assigned to Arm(s): A: Rivaroxaban short arm, B: Rivaroxaban long arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents
Brief Summary: The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular disease events, when compared to atorvastatin alone, in patients with coronary heart disease or risk equivalents


Options:
A: Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lovastatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Pactimibe sulfate; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: torcetrapib/atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects With Multiple Sclerosis With Relapses
Brief Summary: The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS).

Secondary objectives were:

* to evaluate the effect of teriflunomide on the accumulation of disability as measured by Expanded Disability Status Scale \[EDSS\], the burden of disease as measured by Magnetic Resonance Imaging \[MRI\] and patient-reported fatigue;
* to evaluate the safety and tolerability of teriflunomide.


Options:
A: Arm Label: GTR; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (GTR) | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate (Copaxone®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate (GTR); Assigned to Arm(s): GTR | Intervention Type: DRUG; Name: Glatiramer Acetate (Copaxone®); Assigned to Arm(s): Copaxone® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ponesimod; Type: EXPERIMENTAL; Interventions: Drug: ponesimod | Arm Label: Teriflunomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: teriflunomide | Intervention Type: DRUG; Name: ponesimod; Assigned to Arm(s): Ponesimod | Intervention Type: DRUG; Name: teriflunomide; Assigned to Arm(s): Teriflunomide
C: Arm Label: Interferon beta-1a 44 mcg SC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Ocrelizumab-matching placebo | Arm Label: Ocrelizumab; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Drug: Interferon beta-1a-matching placebo | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab-matching placebo; Assigned to Arm(s): Interferon beta-1a 44 mcg SC | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab | Intervention Type: DRUG; Name: Interferon beta-1a-matching placebo; Assigned to Arm(s): Ocrelizumab
D: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects With Multiple Sclerosis With Relapses
Brief Summary: The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS).

Secondary objectives were:

* to evaluate the effect of teriflunomide on the accumulation of disability as measured by Expanded Disability Status Scale \[EDSS\], the burden of disease as measured by Magnetic Resonance Imaging \[MRI\] and patient-reported fatigue;
* to evaluate the safety and tolerability of teriflunomide.


Options:
A: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo
B: Arm Label: Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Teriflunomide, Drug: Placebo | Arm Label: Teriflunomide 7 mg/7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg/14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg, Teriflunomide 14 mg/14 mg, Teriflunomide 7 mg/7 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg
C: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: IFN-β-1a / 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a, Drug: Teriflunomide | Intervention Type: DRUG; Name: Interferon β-1a; Assigned to Arm(s): IFN-β-1a / 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): IFN-β-1a / 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
D: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: teriflunomide (HMR1726) | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: teriflunomide (HMR1726) | Intervention Type: DRUG; Name: teriflunomide (HMR1726); Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects With Multiple Sclerosis With Relapses
Brief Summary: The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS).

Secondary objectives were:

* to evaluate the effect of teriflunomide on the accumulation of disability as measured by Expanded Disability Status Scale \[EDSS\], the burden of disease as measured by Magnetic Resonance Imaging \[MRI\] and patient-reported fatigue;
* to evaluate the safety and tolerability of teriflunomide.


Options:
A: Arm Label: Laquinimod; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Laquinimod | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody); Assigned to Arm(s): N/A
C: Arm Label: FTY720 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: FTY720 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720 0.5 mg, FTY720 1.25 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Increasing CRC Screening in Health Plan Members
Brief Summary: The purpose of this study is to determine the effectiveness of a two-component intervention, that combines academic detailing at the medical practice level and distribution of decision aids at the patient level, on adherence to colorectal cancer screening guidelines.


Options:
A: Intervention Type: BEHAVIORAL; Name: Academic Detailing (Medical Practices)+Decision Aids (Patients); Assigned to Arm(s): N/A
B: Arm Label: Decision Aid; Type: EXPERIMENTAL; Interventions: Other: Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): Decision Aid
C: Arm Label: CDSS-D; Type: EXPERIMENTAL; Interventions: Other: Computerized Decision Support System for Depression (CDSS-D) | Arm Label: UC; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care (UC) | Intervention Type: OTHER; Name: Computerized Decision Support System for Depression (CDSS-D); Assigned to Arm(s): CDSS-D | Intervention Type: OTHER; Name: Usual Care (UC); Assigned to Arm(s): UC
D: Arm Label: Usual Support Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual-Support | Arm Label: Enhanced Support Group; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Support | Intervention Type: BEHAVIORAL; Name: Enhanced Support; Assigned to Arm(s): Enhanced Support Group | Intervention Type: BEHAVIORAL; Name: Usual-Support; Assigned to Arm(s): Usual Support Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Growth of Genitalia Interna and the Bone Mineralization Under Hormonal Replacement Therapy and the Presence of Aortic Root Dilatation in Girls With Turner Syndrome
Brief Summary: The purpose of this study is to examine whether a larger dosage of estrogen than the one used today will secure the development of a normal sized uterus and increase the strength of the bones in girls and young women with Turner syndrome.

The purpose is also to evaluate whether aortic dilatation is present in this group of patients, and if the estrogen dosage will influence the emotional well-being and self-esteem of the patients.


Options:
A: Arm Label: 4 mg estradiol; Type: ACTIVE_COMPARATOR; Interventions: Drug: estradiol | Arm Label: 2 mg estradiol; Type: PLACEBO_COMPARATOR; Interventions: Drug: estradiol | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): 2 mg estradiol, 4 mg estradiol
B: Intervention Type: DRUG; Name: Growth Hormone (Humatrope); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ethinylestradiol / Norethisterone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Estradiol / Progesterone | Intervention Type: DRUG; Name: Ethinylestradiol / Norethisterone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Estradiol / Progesterone; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Pediatric Safety and Quality With Health Care IT
Brief Summary: This study includes four projects aimed to improve the quality and safety of pediatric care through the implementation of four clinical decision support services in the electronic health record (EHR). The four projects will measure the effect of each clinical decision support feature including: weight-based dosing; smart forms for chronic conditions; guideline reminders; and a results manager to track abnormal lab result follow-up.

Hypothesis: Implementation of the clinical decision support features will decrease medication errors and adverse drug events, assist physicians in adhering to clinical practice guidelines and protocols for certain chronic illnesses, improve physician follow-up for abnormal lab results, and overall improve the safety and quality of pediatric clinical practice.


Options:
A: Arm Label: Trained Clinicians; Type: EXPERIMENTAL; Interventions: Behavioral: Training | Arm Label: Non-trained Clinicians; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Non-volunteer Clinicians; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training; Assigned to Arm(s): Trained Clinicians
B: Arm Label: computerized alert; Type: EXPERIMENTAL; Interventions: Drug: Trimethoprim/Sulfamethoxazole and Warfarin | Arm Label: 2 Current practice; Type: OTHER; Interventions: Drug: Trimethoprim/Sulfamethoxazole and Warfarin | Intervention Type: DRUG; Name: Trimethoprim/Sulfamethoxazole and Warfarin; Assigned to Arm(s): 2 Current practice, computerized alert
C: Arm Label: dosing decision support; Type: EXPERIMENTAL; Interventions: Other: weight based dosing decision support | Arm Label: no decision support; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: weight based dosing decision support; Assigned to Arm(s): dosing decision support
D: Arm Label: Receive CDS intervention; Type: EXPERIMENTAL; Interventions: Other: MAPLE | Arm Label: No CDS intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MAPLE; Assigned to Arm(s): Receive CDS intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Pediatric Safety and Quality With Health Care IT
Brief Summary: This study includes four projects aimed to improve the quality and safety of pediatric care through the implementation of four clinical decision support services in the electronic health record (EHR). The four projects will measure the effect of each clinical decision support feature including: weight-based dosing; smart forms for chronic conditions; guideline reminders; and a results manager to track abnormal lab result follow-up.

Hypothesis: Implementation of the clinical decision support features will decrease medication errors and adverse drug events, assist physicians in adhering to clinical practice guidelines and protocols for certain chronic illnesses, improve physician follow-up for abnormal lab results, and overall improve the safety and quality of pediatric clinical practice.


Options:
A: Arm Label: Electronic Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Paper Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Support for ARI Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision Support for ARI Management; Assigned to Arm(s): Electronic Decision Support, Paper Decision Support
B: Arm Label: DECISION+ Program; Type: EXPERIMENTAL; Interventions: Behavioral: Decision+ program (to improve optimal drug prescription for ARI) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision+ program (to improve optimal drug prescription for ARI); Assigned to Arm(s): DECISION+ Program
C: Arm Label: dosing decision support; Type: EXPERIMENTAL; Interventions: Other: weight based dosing decision support | Arm Label: no decision support; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: weight based dosing decision support; Assigned to Arm(s): dosing decision support
D: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Workshops and focus group meetings | Arm Label: Control - no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Workshops and focus group meetings; Assigned to Arm(s): Educational intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventive Primary Care Outreach for High Risk Older Persons
Brief Summary: It is recognized that a significant proportion of seniors over 75 years of age are at risk of functional decline, and thus of institutionalization and death. The investigators at McMaster University Medical Centre, are conducting is a randomized controlled trial of a preventive primary care outreach (PPCO) service provided to high risk seniors living in the community. The goal of this service is to identify unrecognized problems and individuals at increased risk and to link individuals to care. This preventive primary care service is provided by nurse case managers. The investigators have recruited patients through their family physicians who work in primary care networks. The investigators are screening all seniors aged 75 and over within these practices. The sample includes seniors aged 75 and over who are identified to be at risk according to the Sherbrooke Postal Questionnaire. Patients are randomly allocated to intervention and control groups. A research assistant, who is blind to group allocation, will collect data from seniors at baseline, six months, and at the end of one year.

Outcome measures include health-related quality of life (quality adjusted life years \[QALYs\]), health and social service utilization and costs, mortality, institutionalization, functional status, and perceived health status.

Primary Hypothesis:

The intervention compared to usual care will result in higher health-related quality of life.

Secondary Hypotheses:

Compared to usual care, the PPCO intervention will result in:

* the same or lower costs associated with service utilization;
* less functional decline;
* reduced mortality;
* lower rates of institutionalization; and
* better self-rated health.


Options:
A: Intervention Type: BEHAVIORAL; Name: Preventive Primary Care Outreach; Assigned to Arm(s): N/A
B: Arm Label: Conventional care, controlgroup; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: integrated health care chain; Type: EXPERIMENTAL; Interventions: Other: integrated health care chain | Intervention Type: OTHER; Name: integrated health care chain; Assigned to Arm(s): integrated health care chain
C: Intervention Type: BEHAVIORAL; Name: Geriatric Resources for Assessment & Care of Elders (GRACE); Assigned to Arm(s): N/A
D: Arm Label: Control arm= usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention arm; Type: OTHER; Interventions: Other: intervention | Intervention Type: OTHER; Name: intervention; Assigned to Arm(s): Intervention arm

Answer: A